ArticleBMC cancer2026
Detection of IDH1.R132H mutant protein in plasma extracellular vesicles and its application in preoperative noninvasive precision diagnosis of glioma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDevelopment of a circulating extracellular vesicle-based IDH mutant protein detection technology for diagnosis of IDH mutation status in glioma, enabling personalized resection strategies, precision medication, and disease dynamics monitoring in IDH-mutant glioma.
methodsWe developed a tumor-classification strategy that discriminates tumor types by detecting the IDH1.R132H mutant protein in plasma extracellular vesicles using a bead-assisted, flow-cytometry–based assay. We assessed the differential expression’s capacity to distinguish tumor grades, analyzed pre-operative and post-operative expression variations, and verified consistency with histopathological immunohistochemistry.
resultsThe method demonstrated a diagnostic sensitivity of 76.2% (95%CI: 54.9%–89.4%) and a specificity of 86.7% (95%CI: 62.1%–96.3%) for IDH-mutant glioma. Further analysis revealed that the expression level of the IDH mutant protein in plasma EVs was significantly associated with tumor grade in IDH-mutant glioma (P < 0.0001). Moreover, the expression level of the IDH mutant protein in plasma EVs significantly decreased in post-operative patients (P < 0.01) and showed a high degree of consistency with the pathological immunohistochemical results at different tumor grades.
conclusionWe propose a novel plasma extracellular-vesicle liquid biopsy with potential preoperative application in detecting IDH-mutant glioma, affording noninvasive, rapid, efficient, and low-cost assessment of IDH mutation status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.